Janssen Pharmaceutica Products has submitted an application to the U.S. Food and Drug Administration (FDA) permission to market a once-daily formulation of Reminyl for the treatment of mild to moderate Alzheimer's disease in the United States.

Reminyl, which is known generically as galantamine hydrobromide, is already approved for the treatment of mild to moderate Alzheimer's disease in more than 25 countries.

The drug is also being studied in related therapeutic areas, such as vascular dementia and mild cognitive impairment, which is believed to be a precursor to Alzheimer's disease.

Source: Janssen Pharmaceutica Products